Evidence map›Paper›PMID 39095617›Full record

ArticleCommunications biology2024

Glucosylceramide synthase modulation ameliorates murine renal pathologies and promotes macrophage effector function in vitro.

Agnes Cheong, Florin Craciun, Hervé Husson, Joseph Gans, Javier Escobedo, Yi-Chien Chang, Lilu Guo, Mariana Goncalves, Nathan Kaplan, Laurie A Smith and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Agnes CheongRare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA. agnes.cheong@sanofi.com.ORCID 0000-0001-9424-0424
Florin CraciunGenomics Medicine Unit, Sanofi, Waltham, MA, USA.
Hervé HussonGenomics Medicine Unit, Sanofi, Waltham, MA, USA.
Joseph GansTranslational Sciences, Sanofi, Cambridge, MA, USA.
Javier EscobedoGenomics Medicine Unit, Sanofi, Waltham, MA, USA.
Yi-Chien ChangTranslational Sciences, Sanofi, Cambridge, MA, USA.
Lilu GuoTranslational Sciences, Sanofi, Cambridge, MA, USA.
Mariana GoncalvesTranslational Sciences, Sanofi, Cambridge, MA, USA.
Nathan KaplanRare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.
Laurie A SmithRare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.
Sarah MorenoRare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.
Joseph BoulangerResearch and Development Business Office, Sanofi, Cambridge, MA, USA.
Shiguang LiuRare Diseases and Rare Blood Disorders Research, Sanofi, Cambridge, MA, USA.
Jacqueline SalehRare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.
Mindy ZhangTranslational Sciences, Sanofi, Cambridge, MA, USA.
Anna S BlazierRare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.
Weiliang QiuNon-Clinical Efficacy & Safety, Sanofi, Cambridge, MA, USA.
Andrew MacklinRare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.
Tejaswi IyyankiPrecision Medicine and Computational Biology, Sanofi, Cambridge, MA, USA.
Clément ChatelainPrecision Medicine and Computational Biology, Sanofi, Cambridge, MA, USA.
Shameer KhaderPrecision Medicine and Computational Biology, Sanofi, Cambridge, MA, USA.
Thomas A NatoliRare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.ORCID 0000-0002-7949-022X
Oxana Ibraghimov-BeskrovnayaRare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.
Dimitry OfengeimRare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.ORCID 0000-0003-2348-3642
Jonathan D ProtoRare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA. jproto@neurocrine.com.ORCID 0009-0005-9950-4720

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While significant advances have been made in understanding renal pathophysiology, less is known about the role of glycosphingolipid (GSL) metabolism in driving organ dysfunction. Here, we used a small molecule inhibitor of glucosylceramide synthase to modulate GSL levels in three mouse models of distinct renal pathologies: Alport syndrome (Col4a3 KO), polycystic kidney disease (Nek8

Indexed as

GlucosyltransferasesMacrophagesAnimalsDisease Models, AnimalKidneyMaleMiceMice, Inbred C57BLMice, Knockoutceramide glucosyltransferaseGlucosyltransferases

Identifiers

PMID39095617
PMCPMC11297156

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.